Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry

Author(s):  
Zobair M. Younossi ◽  
Yusuf Yilmaz ◽  
Ming-Lung Yu ◽  
Vincent Wai-Sun Wong ◽  
Marlen Castellanos Fernandez ◽  
...  
2022 ◽  
Author(s):  
Mio Yamamoto ◽  
Yasukiyo Yoshioka ◽  
Tomoya Kitakaze ◽  
Yoko Yamashita ◽  
Hitoshi Ashida

Non-alcoholic fatty liver disease (NAFLD) and its advanced stage, non-alcoholic steatohepatitis (NASH) are a major health issue throughout the world. Certain food components such as polyphenols are expected to possess...


2020 ◽  
Vol 37 (11) ◽  
pp. 4627-4640
Author(s):  
Igor V. Maev ◽  
Alexey A. Samsonov ◽  
Leonid B. Lazebnik ◽  
Elena V. Golovanova ◽  
Chavdar S. Pavlov ◽  
...  

2022 ◽  
Vol 8 (1) ◽  
Author(s):  
Aman Sharma

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is now the most common form of chronic liver disease in the world, and it’s linked to a slew of other risk factors including diabetes, obesity, dysbiosis and inflammatory bowel disease. More than 30 years ago, a patient was diagnosed with fatty liver with excessive fat accumulation in hepatocytes, a disorder known as hepatosteatosis. There will be no promising therapeutic medicines available from 1980 to 2021 which can reverse the fatty liver to normal liver state. In this review, we highlighted on lipid droplet associated protein which play a major role in accumulation of fat in liver cells and how these cellular pathway could be a promising therapeutic approach to treat the fatty liver disease. Main body Over the last few decades, Western countries follow a high-fat diet and change their lifestyle pattern due to certain metabolic disorders prevalence rate is very high all over the world. NAFLD is a major health issue and burden globally nowadays. Researchers are trying to find out the potential therapeutic target to combat the disease. The exact pathophysiology of the disease is still unclear. In the present decades. There is no Food and Drug Administration approved drugs are available to reverse the chronic condition of the disease. Based on literature survey, lipid droplets and their associated protein like perilipins play an eminent role in body fat regulation. In this review, we explain all types of perilipins such as perilipin1-5 (PLIN1-5) and their role in the pathogenesis of fatty liver which will be helpful to find the novel pharmacological target to treat the fatty liver. Conclusion In this review, majorly focussed on how fat is get deposited into hepatocytes follow the cellular signalling involved during lipid droplet biogenesis and leads to NAFLD. However, up to date still there mechanism of action is unclear. In this review, we hypothesized that lipid droplets associated proteins like perilipins could be better pharmacological target to reverse the chronic stage of fatty liver disease and how these lipid droplets associated proteins hide a clue to maintain the normal lipid homeostasis in the human body.


RSC Advances ◽  
2019 ◽  
Vol 9 (20) ◽  
pp. 11406-11412
Author(s):  
V. Sorrenti ◽  
C. Di Giacomo ◽  
R. Acquaviva ◽  
J. Cosenza ◽  
G. Carota ◽  
...  

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease spread throughout the world.


2021 ◽  
Vol 9 (11) ◽  
pp. 2797-2801
Author(s):  
Aparna Chandran ◽  
Mahadevan L. ◽  
Nisha M.G ◽  
Arun Pratap

Non-Alcoholic Fatty Liver Disease (NAFLD) is a distinct hepatic condition characterized by abnormal fat accumu- lation in liver cells and histologically it resembles alcohol-induced liver damage. The prevalence of NAFLD is up to 30% in developed countries and 10% in developing nations, making NAFLD the most common liver condition in the world. The liver can be compared with Yakrit (Liver) mentioned in Ayurvedic classics as an important Ko- shtanga (organ of the gastrointestinal system). But NAFLD as such could not be correlated to any of the Yakrit Rogas (Liver disorders) mentioned in Ayurvedic classics. Understanding the Nidana (aetiology) and Samprapti (pathogenesis) of the disease, NAFLD can be considered as a Santarpanajanya Vyadhi (disease due to over nour- ishment). Here initially Agnivikruti (deranged digestive fire) occurs which leads to the formation of Ama (Free radicals) which results from the vitiation of Kaphadosha and further results in unequal formation and deposition of Dushta Vasa (triglycerides) in Yakrit. Hence Agnideepana (stimulating digestive fire), Amapachana (antioxidation), Lekhana (scraping), Srotosodhana (clearing of channels of circulation), Kapha Medohara (antihyperlipidemic) and Vataanulomana (normalising the movement of Vata) is aimed primarily in the management of NAFLD Keywords: Non-Alcoholic Fatty Liver Disease, Ultrasonography, Liver Function Test, Santarpanajanya Vyadhi


BMC Medicine ◽  
2018 ◽  
Vol 16 (1) ◽  
Author(s):  
Myriam Alexander ◽  
A. Katrina Loomis ◽  
Jolyon Fairburn-Beech ◽  
Johan van der Lei ◽  
Talita Duarte-Salles ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document